Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Exercise Tolerance | 53 | 2023 | 770 | 8.120 |
Why?
|
Exercise Test | 67 | 2023 | 2074 | 7.440 |
Why?
|
Heart Failure | 103 | 2024 | 10900 | 7.330 |
Why?
|
Stroke Volume | 67 | 2024 | 5007 | 5.030 |
Why?
|
Oxygen Consumption | 30 | 2023 | 1869 | 4.410 |
Why?
|
Hypertension, Pulmonary | 19 | 2023 | 1537 | 3.490 |
Why?
|
Exercise | 33 | 2023 | 5615 | 2.890 |
Why?
|
Anemia, Iron-Deficiency | 7 | 2023 | 365 | 2.560 |
Why?
|
Ventricular Function, Left | 28 | 2023 | 3670 | 2.320 |
Why?
|
Hemodynamics | 20 | 2023 | 4199 | 2.300 |
Why?
|
Ventricular Dysfunction, Left | 11 | 2022 | 2073 | 1.960 |
Why?
|
Pulmonary Wedge Pressure | 10 | 2023 | 264 | 1.880 |
Why?
|
Hematinics | 4 | 2023 | 281 | 1.720 |
Why?
|
Heart Failure, Systolic | 4 | 2015 | 126 | 1.720 |
Why?
|
Dyspnea | 8 | 2023 | 1303 | 1.540 |
Why?
|
Heart Rate | 16 | 2021 | 4091 | 1.520 |
Why?
|
Vascular Resistance | 10 | 2022 | 936 | 1.460 |
Why?
|
Heart-Assist Devices | 10 | 2022 | 1194 | 1.370 |
Why?
|
Ventricular Function, Right | 6 | 2018 | 591 | 1.340 |
Why?
|
Iron Compounds | 3 | 2019 | 20 | 1.330 |
Why?
|
Cardiac Output | 8 | 2018 | 854 | 1.220 |
Why?
|
Ventricular Dysfunction, Right | 5 | 2016 | 581 | 1.190 |
Why?
|
Pulmonary Ventilation | 5 | 2023 | 373 | 1.190 |
Why?
|
Metabolome | 7 | 2020 | 895 | 1.070 |
Why?
|
Phosphodiesterase Inhibitors | 5 | 2012 | 215 | 1.050 |
Why?
|
Sulfones | 10 | 2014 | 437 | 1.050 |
Why?
|
Phosphodiesterase 5 Inhibitors | 10 | 2019 | 101 | 1.040 |
Why?
|
Oxygen | 9 | 2023 | 4189 | 1.030 |
Why?
|
Heart Transplantation | 14 | 2023 | 3110 | 1.010 |
Why?
|
Purines | 12 | 2016 | 594 | 0.960 |
Why?
|
Pulmonary Circulation | 5 | 2016 | 739 | 0.930 |
Why?
|
Piperazines | 12 | 2015 | 2488 | 0.930 |
Why?
|
Ferric Compounds | 5 | 2024 | 374 | 0.920 |
Why?
|
Pulmonary Gas Exchange | 8 | 2020 | 382 | 0.910 |
Why?
|
Pulmonary Artery | 6 | 2022 | 1912 | 0.870 |
Why?
|
Respiratory Protective Devices | 1 | 2020 | 45 | 0.750 |
Why?
|
Humans | 198 | 2024 | 744343 | 0.720 |
Why?
|
Urea | 1 | 2022 | 450 | 0.720 |
Why?
|
Middle Aged | 101 | 2023 | 213383 | 0.680 |
Why?
|
Ferritins | 4 | 2021 | 590 | 0.670 |
Why?
|
Heart Ventricles | 8 | 2020 | 3821 | 0.640 |
Why?
|
Male | 128 | 2023 | 350118 | 0.640 |
Why?
|
Cardiomyopathy, Hypertrophic | 3 | 2023 | 1265 | 0.630 |
Why?
|
Cardiovascular Diseases | 14 | 2022 | 15165 | 0.620 |
Why?
|
Blood Pressure | 15 | 2022 | 8554 | 0.610 |
Why?
|
Ventricular Remodeling | 9 | 2018 | 1224 | 0.600 |
Why?
|
Aged | 73 | 2023 | 163280 | 0.600 |
Why?
|
Cheyne-Stokes Respiration | 2 | 2014 | 38 | 0.560 |
Why?
|
Metabolomics | 3 | 2020 | 1484 | 0.560 |
Why?
|
Cardiac Resynchronization Therapy | 4 | 2016 | 531 | 0.550 |
Why?
|
Tricarboxylic Acids | 1 | 2016 | 29 | 0.550 |
Why?
|
Female | 118 | 2023 | 380194 | 0.550 |
Why?
|
Hypertrophy, Left Ventricular | 6 | 2017 | 859 | 0.540 |
Why?
|
3',5'-Cyclic-GMP Phosphodiesterases | 2 | 2006 | 56 | 0.540 |
Why?
|
Cardiovascular Agents | 1 | 2022 | 850 | 0.540 |
Why?
|
Natriuretic Peptide, Brain | 11 | 2022 | 1573 | 0.520 |
Why?
|
Heart | 6 | 2022 | 4467 | 0.520 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2016 | 109 | 0.520 |
Why?
|
Tissue Donors | 4 | 2023 | 2240 | 0.490 |
Why?
|
Health Status | 6 | 2023 | 4034 | 0.490 |
Why?
|
Double-Blind Method | 18 | 2023 | 12026 | 0.480 |
Why?
|
Hypertrophy, Right Ventricular | 1 | 2014 | 110 | 0.470 |
Why?
|
Physical Endurance | 5 | 2017 | 370 | 0.450 |
Why?
|
Maltose | 2 | 2024 | 34 | 0.440 |
Why?
|
Mitral Valve | 1 | 2021 | 1491 | 0.440 |
Why?
|
Physical Fitness | 5 | 2022 | 733 | 0.420 |
Why?
|
Arginine | 1 | 2016 | 944 | 0.410 |
Why?
|
Angiotensin Receptor Antagonists | 4 | 2023 | 924 | 0.410 |
Why?
|
Vasodilator Agents | 6 | 2016 | 977 | 0.410 |
Why?
|
Mitral Valve Insufficiency | 2 | 2021 | 1422 | 0.410 |
Why?
|
Physical Exertion | 3 | 2023 | 695 | 0.400 |
Why?
|
Fractional Flow Reserve, Myocardial | 1 | 2015 | 290 | 0.400 |
Why?
|
Aldosterone | 2 | 2015 | 877 | 0.390 |
Why?
|
Peptide Fragments | 11 | 2022 | 5097 | 0.390 |
Why?
|
Hepatitis C, Chronic | 1 | 2019 | 1031 | 0.380 |
Why?
|
Tricuspid Valve Insufficiency | 1 | 2014 | 349 | 0.380 |
Why?
|
Adult | 55 | 2023 | 214055 | 0.380 |
Why?
|
Metabolic Networks and Pathways | 3 | 2012 | 783 | 0.370 |
Why?
|
Lung | 4 | 2022 | 9856 | 0.370 |
Why?
|
Respiration | 3 | 2022 | 1653 | 0.360 |
Why?
|
Body Mass Index | 6 | 2024 | 12720 | 0.360 |
Why?
|
Myocardial Contraction | 5 | 2022 | 1585 | 0.360 |
Why?
|
Nitric Oxide | 3 | 2016 | 2132 | 0.350 |
Why?
|
Prognosis | 14 | 2022 | 29063 | 0.340 |
Why?
|
Obesity | 13 | 2023 | 12745 | 0.340 |
Why?
|
Polysaccharides | 1 | 2016 | 1053 | 0.340 |
Why?
|
Time Factors | 23 | 2020 | 40075 | 0.340 |
Why?
|
Muscle Tonus | 1 | 2008 | 81 | 0.330 |
Why?
|
Myocardium | 5 | 2020 | 4776 | 0.330 |
Why?
|
Systole | 4 | 2020 | 958 | 0.330 |
Why?
|
Quality of Life | 13 | 2023 | 12804 | 0.320 |
Why?
|
Athletes | 5 | 2023 | 1093 | 0.320 |
Why?
|
Iron | 4 | 2023 | 1774 | 0.310 |
Why?
|
Blood | 1 | 2010 | 598 | 0.310 |
Why?
|
Phenotype | 9 | 2023 | 16365 | 0.300 |
Why?
|
Heart Diseases | 3 | 2020 | 2788 | 0.300 |
Why?
|
Respiratory Mechanics | 1 | 2011 | 686 | 0.300 |
Why?
|
Transferrin | 3 | 2019 | 295 | 0.290 |
Why?
|
Echocardiography | 10 | 2021 | 5102 | 0.290 |
Why?
|
Helicobacter | 1 | 2007 | 112 | 0.290 |
Why?
|
Antiviral Agents | 1 | 2019 | 2987 | 0.290 |
Why?
|
Lung Diseases, Interstitial | 1 | 2015 | 808 | 0.290 |
Why?
|
Heart Injuries | 1 | 2008 | 210 | 0.280 |
Why?
|
Predictive Value of Tests | 10 | 2021 | 15076 | 0.280 |
Why?
|
Treatment Outcome | 26 | 2024 | 63114 | 0.280 |
Why?
|
Benzhydryl Compounds | 2 | 2023 | 845 | 0.280 |
Why?
|
Prospective Studies | 28 | 2022 | 53288 | 0.280 |
Why?
|
Administration, Oral | 6 | 2020 | 3913 | 0.280 |
Why?
|
Muscle, Skeletal | 5 | 2017 | 4931 | 0.270 |
Why?
|
Biomedical Technology | 1 | 2008 | 220 | 0.270 |
Why?
|
Pericarditis | 1 | 2007 | 128 | 0.270 |
Why?
|
Respiratory Function Tests | 3 | 2021 | 1616 | 0.260 |
Why?
|
Pulmonary Veins | 1 | 2011 | 761 | 0.250 |
Why?
|
Insulin Resistance | 7 | 2023 | 3864 | 0.250 |
Why?
|
Waiting Lists | 2 | 2019 | 692 | 0.250 |
Why?
|
Sequoia | 1 | 2023 | 6 | 0.240 |
Why?
|
Energy Metabolism | 2 | 2017 | 2899 | 0.230 |
Why?
|
Cardiovascular System | 2 | 2022 | 832 | 0.230 |
Why?
|
Follow-Up Studies | 16 | 2020 | 39050 | 0.230 |
Why?
|
Helicobacter Infections | 1 | 2007 | 386 | 0.230 |
Why?
|
Models, Cardiovascular | 3 | 2016 | 996 | 0.230 |
Why?
|
Retrospective Studies | 20 | 2024 | 77449 | 0.230 |
Why?
|
Anaerobic Threshold | 2 | 2015 | 52 | 0.230 |
Why?
|
Vascular Patency | 1 | 2006 | 886 | 0.230 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 7913 | 0.220 |
Why?
|
Lung Diseases | 1 | 2013 | 1886 | 0.220 |
Why?
|
Tissue and Organ Procurement | 2 | 2023 | 896 | 0.220 |
Why?
|
Sulfonamides | 3 | 2019 | 1938 | 0.220 |
Why?
|
Coronary Thrombosis | 1 | 2006 | 495 | 0.220 |
Why?
|
Feasibility Studies | 3 | 2021 | 5078 | 0.210 |
Why?
|
Dietary Supplements | 3 | 2023 | 3297 | 0.210 |
Why?
|
Expert Testimony | 2 | 2022 | 356 | 0.210 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2008 | 1504 | 0.210 |
Why?
|
Environmental Microbiology | 1 | 2002 | 46 | 0.210 |
Why?
|
Cohort Studies | 14 | 2021 | 40561 | 0.200 |
Why?
|
Ventriculography, First-Pass | 2 | 2013 | 20 | 0.200 |
Why?
|
Heart Septal Defects, Ventricular | 1 | 2004 | 488 | 0.200 |
Why?
|
Organ Transplantation | 2 | 2022 | 1139 | 0.200 |
Why?
|
Sodium-Glucose Transporter 2 | 1 | 2021 | 85 | 0.200 |
Why?
|
Risk Assessment | 8 | 2021 | 23338 | 0.200 |
Why?
|
Diabetic Cardiomyopathies | 1 | 2022 | 96 | 0.200 |
Why?
|
Enterovirus | 1 | 2002 | 64 | 0.200 |
Why?
|
Myocardial Ischemia | 6 | 2014 | 2148 | 0.200 |
Why?
|
Pulmonary Embolism | 2 | 2023 | 2376 | 0.190 |
Why?
|
Heart Failure, Diastolic | 1 | 2021 | 69 | 0.190 |
Why?
|
Autonomic Denervation | 1 | 2020 | 6 | 0.190 |
Why?
|
Myocytes, Cardiac | 3 | 2016 | 1637 | 0.190 |
Why?
|
Running | 2 | 2015 | 480 | 0.180 |
Why?
|
Drug Combinations | 3 | 2022 | 1959 | 0.180 |
Why?
|
Biphenyl Compounds | 2 | 2022 | 913 | 0.180 |
Why?
|
MicroRNAs | 5 | 2018 | 3752 | 0.180 |
Why?
|
Pyrazoles | 2 | 2020 | 1972 | 0.180 |
Why?
|
Multicenter Studies as Topic | 2 | 2022 | 1677 | 0.180 |
Why?
|
Myocarditis | 1 | 2007 | 771 | 0.170 |
Why?
|
Recovery of Function | 6 | 2020 | 2925 | 0.170 |
Why?
|
Cardiac Pacing, Artificial | 2 | 2014 | 845 | 0.170 |
Why?
|
Reference Values | 3 | 2015 | 4982 | 0.170 |
Why?
|
Longitudinal Studies | 10 | 2021 | 13989 | 0.160 |
Why?
|
Angina Pectoris | 2 | 2014 | 977 | 0.160 |
Why?
|
Growth Differentiation Factor 15 | 1 | 2019 | 176 | 0.160 |
Why?
|
Nitrites | 1 | 2018 | 160 | 0.160 |
Why?
|
Coronary Occlusion | 1 | 2021 | 304 | 0.160 |
Why?
|
Sternotomy | 1 | 2019 | 121 | 0.160 |
Why?
|
Walking | 2 | 2023 | 1180 | 0.160 |
Why?
|
Pyrimidines | 2 | 2020 | 2942 | 0.160 |
Why?
|
Ultrasonic Therapy | 1 | 2020 | 235 | 0.160 |
Why?
|
Galectin 3 | 1 | 2019 | 227 | 0.160 |
Why?
|
Rest | 2 | 2014 | 901 | 0.150 |
Why?
|
Myocardial Infarction | 4 | 2018 | 11727 | 0.150 |
Why?
|
Glucosides | 1 | 2021 | 451 | 0.150 |
Why?
|
Adenoviridae | 1 | 2002 | 1099 | 0.150 |
Why?
|
Linear Models | 3 | 2020 | 5952 | 0.150 |
Why?
|
Chagas Disease | 1 | 2019 | 166 | 0.150 |
Why?
|
Quinoxalines | 1 | 2019 | 290 | 0.150 |
Why?
|
Extracellular Matrix Proteins | 1 | 2021 | 849 | 0.150 |
Why?
|
Pyrrolidines | 1 | 2019 | 342 | 0.150 |
Why?
|
Young Adult | 19 | 2022 | 56430 | 0.150 |
Why?
|
Trypanosoma cruzi | 1 | 2019 | 198 | 0.150 |
Why?
|
Triglycerides | 3 | 2016 | 2454 | 0.150 |
Why?
|
Extracorporeal Membrane Oxygenation | 2 | 2020 | 1354 | 0.150 |
Why?
|
Sarcomeres | 1 | 2019 | 374 | 0.140 |
Why?
|
Diet, Mediterranean | 1 | 2023 | 700 | 0.140 |
Why?
|
Donor Selection | 1 | 2018 | 201 | 0.140 |
Why?
|
Reproducibility of Results | 6 | 2020 | 19905 | 0.140 |
Why?
|
Calcium-Binding Proteins | 1 | 2021 | 1081 | 0.140 |
Why?
|
Polymyxins | 1 | 2016 | 22 | 0.140 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2019 | 451 | 0.140 |
Why?
|
Creatinine | 2 | 2019 | 1919 | 0.140 |
Why?
|
Diastole | 2 | 2016 | 791 | 0.140 |
Why?
|
Trimethoprim | 1 | 2016 | 91 | 0.140 |
Why?
|
Blood Volume | 1 | 2017 | 565 | 0.140 |
Why?
|
Graft Survival | 3 | 2023 | 3737 | 0.140 |
Why?
|
Fibrinolytic Agents | 1 | 2006 | 2158 | 0.140 |
Why?
|
Amino Acids, Aromatic | 2 | 2012 | 32 | 0.140 |
Why?
|
Cyclic Nucleotide Phosphodiesterases, Type 5 | 2 | 2006 | 34 | 0.140 |
Why?
|
Mucopolysaccharidosis IV | 1 | 2015 | 7 | 0.130 |
Why?
|
Nitrates | 1 | 2017 | 265 | 0.130 |
Why?
|
Carbon Dioxide | 2 | 2011 | 1150 | 0.130 |
Why?
|
Chondroitinsulfatases | 1 | 2015 | 16 | 0.130 |
Why?
|
Risk Factors | 14 | 2022 | 72290 | 0.130 |
Why?
|
Immunomodulation | 1 | 2019 | 541 | 0.130 |
Why?
|
Diabetes Complications | 1 | 2022 | 1359 | 0.130 |
Why?
|
Hepacivirus | 2 | 2020 | 1379 | 0.130 |
Why?
|
Competitive Behavior | 1 | 2015 | 74 | 0.130 |
Why?
|
Atrial Function, Left | 2 | 2015 | 173 | 0.130 |
Why?
|
Glomerular Filtration Rate | 2 | 2020 | 2170 | 0.130 |
Why?
|
Enzyme Replacement Therapy | 1 | 2015 | 78 | 0.130 |
Why?
|
Coronary Artery Disease | 4 | 2021 | 6487 | 0.130 |
Why?
|
RNA, Transfer | 1 | 2017 | 316 | 0.130 |
Why?
|
Naval Medicine | 1 | 2014 | 31 | 0.130 |
Why?
|
Glucose Tolerance Test | 4 | 2014 | 1150 | 0.130 |
Why?
|
Echocardiography, Doppler | 5 | 2017 | 935 | 0.120 |
Why?
|
Case-Control Studies | 7 | 2018 | 21746 | 0.120 |
Why?
|
Ancillary Services, Hospital | 1 | 2014 | 23 | 0.120 |
Why?
|
Tetrazoles | 1 | 2020 | 835 | 0.120 |
Why?
|
Cerebrum | 1 | 2016 | 137 | 0.120 |
Why?
|
Coronary Vessels | 1 | 2006 | 3107 | 0.120 |
Why?
|
Massachusetts | 3 | 2020 | 8663 | 0.120 |
Why?
|
Aminoisobutyric Acids | 1 | 2014 | 38 | 0.120 |
Why?
|
Magnetic Resonance Imaging, Cine | 2 | 2018 | 964 | 0.120 |
Why?
|
Ventricular Pressure | 2 | 2012 | 199 | 0.120 |
Why?
|
Bariatric Surgery | 1 | 2024 | 952 | 0.120 |
Why?
|
Kaplan-Meier Estimate | 5 | 2016 | 6538 | 0.120 |
Why?
|
Benzimidazoles | 1 | 2019 | 850 | 0.120 |
Why?
|
Proportional Hazards Models | 3 | 2018 | 12354 | 0.120 |
Why?
|
Communicable Disease Control | 1 | 2021 | 857 | 0.120 |
Why?
|
Aortic Diseases | 1 | 2020 | 742 | 0.120 |
Why?
|
Endothelin-1 | 1 | 2015 | 314 | 0.120 |
Why?
|
Cardiac Resynchronization Therapy Devices | 1 | 2015 | 124 | 0.120 |
Why?
|
Animals | 20 | 2022 | 168757 | 0.110 |
Why?
|
Pilot Projects | 5 | 2023 | 8324 | 0.110 |
Why?
|
Chronic Disease | 4 | 2022 | 9146 | 0.110 |
Why?
|
Amino Acids, Branched-Chain | 2 | 2012 | 251 | 0.110 |
Why?
|
Adaptation, Physiological | 5 | 2017 | 1312 | 0.110 |
Why?
|
Obesity, Morbid | 1 | 2024 | 1213 | 0.110 |
Why?
|
Injections, Intravenous | 1 | 2015 | 1420 | 0.110 |
Why?
|
Carbolines | 1 | 2014 | 265 | 0.110 |
Why?
|
Endothelium, Vascular | 2 | 2015 | 4456 | 0.110 |
Why?
|
Heart Valve Prosthesis | 1 | 2021 | 1488 | 0.110 |
Why?
|
Hypertension | 4 | 2022 | 8480 | 0.110 |
Why?
|
Coronary Sinus | 2 | 2014 | 87 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2024 | 9959 | 0.110 |
Why?
|
Propensity Score | 1 | 2019 | 1781 | 0.110 |
Why?
|
Polymerase Chain Reaction | 1 | 2002 | 6171 | 0.100 |
Why?
|
Aorta | 1 | 2020 | 2061 | 0.100 |
Why?
|
Inflammation Mediators | 1 | 2021 | 1889 | 0.100 |
Why?
|
Bile Acids and Salts | 1 | 2014 | 367 | 0.100 |
Why?
|
Sports Medicine | 1 | 2014 | 225 | 0.100 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2023 | 11725 | 0.100 |
Why?
|
Eicosanoids | 2 | 2023 | 279 | 0.100 |
Why?
|
Laparoscopy | 1 | 2024 | 2151 | 0.100 |
Why?
|
Blood Glucose | 3 | 2019 | 6256 | 0.100 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2012 | 153 | 0.100 |
Why?
|
Device Removal | 1 | 2017 | 656 | 0.100 |
Why?
|
Sex Factors | 5 | 2020 | 10397 | 0.100 |
Why?
|
Natriuretic Peptides | 1 | 2012 | 150 | 0.100 |
Why?
|
Adiponectin | 3 | 2023 | 1100 | 0.100 |
Why?
|
Adolescent | 16 | 2021 | 85781 | 0.100 |
Why?
|
Peptide Mapping | 1 | 2011 | 263 | 0.100 |
Why?
|
Football | 1 | 2016 | 460 | 0.100 |
Why?
|
Proteomics | 2 | 2023 | 3638 | 0.100 |
Why?
|
Adipose Tissue, White | 1 | 2014 | 351 | 0.100 |
Why?
|
Capillaries | 1 | 2014 | 773 | 0.100 |
Why?
|
Antihypertensive Agents | 2 | 2020 | 2046 | 0.090 |
Why?
|
Heart Atria | 1 | 2016 | 1357 | 0.090 |
Why?
|
Blood Gas Analysis | 1 | 2011 | 383 | 0.090 |
Why?
|
Sodium Chloride | 1 | 2012 | 625 | 0.090 |
Why?
|
Diffusion Tensor Imaging | 1 | 2020 | 2305 | 0.090 |
Why?
|
Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2010 | 70 | 0.090 |
Why?
|
Prosthesis-Related Infections | 1 | 2016 | 538 | 0.090 |
Why?
|
Hepatitis C | 1 | 2020 | 1591 | 0.090 |
Why?
|
Clinical Protocols | 1 | 2016 | 1462 | 0.090 |
Why?
|
Mass Spectrometry | 3 | 2014 | 2203 | 0.090 |
Why?
|
Shock, Cardiogenic | 1 | 2015 | 688 | 0.090 |
Why?
|
Hypothyroidism | 1 | 2015 | 658 | 0.090 |
Why?
|
Tandem Mass Spectrometry | 3 | 2011 | 1157 | 0.090 |
Why?
|
Diuretics | 1 | 2012 | 592 | 0.090 |
Why?
|
Blood Chemical Analysis | 1 | 2011 | 440 | 0.090 |
Why?
|
Body Composition | 1 | 2019 | 2401 | 0.090 |
Why?
|
Leptin | 3 | 2023 | 1599 | 0.080 |
Why?
|
Statistics as Topic | 1 | 2016 | 2373 | 0.080 |
Why?
|
Apoptosis | 2 | 2016 | 9727 | 0.080 |
Why?
|
Chromatography, Liquid | 2 | 2010 | 976 | 0.080 |
Why?
|
Uremia | 1 | 2010 | 201 | 0.080 |
Why?
|
Administration, Inhalation | 2 | 2018 | 1105 | 0.080 |
Why?
|
Interleukin-6 | 4 | 2023 | 3200 | 0.080 |
Why?
|
Isotopes | 1 | 2008 | 124 | 0.080 |
Why?
|
Severity of Illness Index | 6 | 2016 | 15540 | 0.080 |
Why?
|
Chi-Square Distribution | 1 | 2015 | 3508 | 0.080 |
Why?
|
Aged, 80 and over | 7 | 2019 | 57776 | 0.080 |
Why?
|
Diabetes Mellitus | 4 | 2020 | 5751 | 0.080 |
Why?
|
Sports | 1 | 2014 | 688 | 0.080 |
Why?
|
Age Factors | 5 | 2018 | 18370 | 0.080 |
Why?
|
Biological Assay | 1 | 2011 | 652 | 0.080 |
Why?
|
Fatty Acids | 1 | 2016 | 1809 | 0.080 |
Why?
|
Renin-Angiotensin System | 1 | 2012 | 759 | 0.080 |
Why?
|
Adipose Tissue, Brown | 1 | 2014 | 757 | 0.080 |
Why?
|
Comorbidity | 3 | 2017 | 10388 | 0.080 |
Why?
|
Vasodilation | 2 | 2015 | 944 | 0.080 |
Why?
|
Heart Defects, Congenital | 2 | 2014 | 4584 | 0.080 |
Why?
|
Diabetic Angiopathies | 1 | 2012 | 818 | 0.070 |
Why?
|
Metabolic Diseases | 1 | 2014 | 658 | 0.070 |
Why?
|
Kinetics | 3 | 2010 | 6473 | 0.070 |
Why?
|
Swine | 3 | 2022 | 5917 | 0.070 |
Why?
|
Dogs | 2 | 2015 | 3912 | 0.070 |
Why?
|
Opioid-Related Disorders | 1 | 2021 | 2065 | 0.070 |
Why?
|
Logistic Models | 3 | 2020 | 13408 | 0.070 |
Why?
|
Troponin T | 1 | 2011 | 754 | 0.070 |
Why?
|
Weight Loss | 2 | 2024 | 2622 | 0.070 |
Why?
|
Graft Rejection | 1 | 2019 | 4397 | 0.070 |
Why?
|
Cardiac Output, Low | 1 | 2006 | 195 | 0.070 |
Why?
|
Aging | 3 | 2021 | 8664 | 0.070 |
Why?
|
Sex Characteristics | 4 | 2020 | 2585 | 0.070 |
Why?
|
Multivariate Analysis | 2 | 2016 | 12245 | 0.060 |
Why?
|
Inflammation | 3 | 2023 | 10638 | 0.060 |
Why?
|
Exercise Therapy | 1 | 2012 | 906 | 0.060 |
Why?
|
Data Mining | 1 | 2010 | 537 | 0.060 |
Why?
|
Mice | 8 | 2021 | 81183 | 0.060 |
Why?
|
Transplantation, Heterologous | 3 | 2022 | 2382 | 0.060 |
Why?
|
Kidney Transplantation | 1 | 2020 | 4251 | 0.060 |
Why?
|
Reference Standards | 1 | 2008 | 1025 | 0.060 |
Why?
|
Periodicity | 1 | 2006 | 363 | 0.060 |
Why?
|
Arrhythmias, Cardiac | 1 | 2014 | 2268 | 0.060 |
Why?
|
Registries | 2 | 2022 | 8089 | 0.060 |
Why?
|
Mortality | 1 | 2016 | 2864 | 0.060 |
Why?
|
Microcirculation | 1 | 2009 | 1286 | 0.060 |
Why?
|
Glucose Intolerance | 1 | 2008 | 577 | 0.060 |
Why?
|
Kidney | 1 | 2019 | 7186 | 0.060 |
Why?
|
Phosphoric Diester Hydrolases | 1 | 2004 | 197 | 0.060 |
Why?
|
Hospitalization | 5 | 2024 | 10262 | 0.060 |
Why?
|
Lipids | 2 | 2015 | 3305 | 0.060 |
Why?
|
Survival Rate | 4 | 2019 | 12788 | 0.060 |
Why?
|
Treatment Failure | 2 | 2020 | 2618 | 0.060 |
Why?
|
Telemedicine | 1 | 2021 | 2872 | 0.060 |
Why?
|
Pandemics | 2 | 2020 | 8388 | 0.060 |
Why?
|
Cyclic GMP | 1 | 2004 | 409 | 0.060 |
Why?
|
Epoxy Compounds | 1 | 2023 | 136 | 0.060 |
Why?
|
United States | 9 | 2023 | 69872 | 0.060 |
Why?
|
Kidney Failure, Chronic | 2 | 2020 | 2538 | 0.060 |
Why?
|
Aldehyde Reductase | 1 | 2022 | 65 | 0.060 |
Why?
|
Prediabetic State | 1 | 2008 | 499 | 0.050 |
Why?
|
Principal Component Analysis | 2 | 2020 | 940 | 0.050 |
Why?
|
Resistin | 1 | 2023 | 170 | 0.050 |
Why?
|
Incidence | 4 | 2019 | 20947 | 0.050 |
Why?
|
Platelet Aggregation | 1 | 2006 | 798 | 0.050 |
Why?
|
Linoleic Acid | 1 | 2023 | 157 | 0.050 |
Why?
|
Recurrence | 1 | 2014 | 8340 | 0.050 |
Why?
|
Europe | 2 | 2020 | 3339 | 0.050 |
Why?
|
Confidence Intervals | 1 | 2008 | 2971 | 0.050 |
Why?
|
Sewage | 1 | 2002 | 40 | 0.050 |
Why?
|
Psychomotor Performance | 1 | 2010 | 1901 | 0.050 |
Why?
|
Pulse | 1 | 2021 | 229 | 0.050 |
Why?
|
Signal Transduction | 2 | 2021 | 23403 | 0.050 |
Why?
|
Proteome | 1 | 2011 | 1799 | 0.050 |
Why?
|
Water Microbiology | 1 | 2002 | 117 | 0.050 |
Why?
|
Insulin | 3 | 2014 | 6580 | 0.050 |
Why?
|
Ultrasonography | 4 | 2016 | 5985 | 0.050 |
Why?
|
Bronchodilator Agents | 1 | 2004 | 502 | 0.050 |
Why?
|
Patient Care Team | 1 | 2012 | 2531 | 0.050 |
Why?
|
Lipolysis | 2 | 2014 | 210 | 0.050 |
Why?
|
Early Termination of Clinical Trials | 1 | 2020 | 68 | 0.050 |
Why?
|
Plasma Volume | 1 | 2019 | 36 | 0.050 |
Why?
|
Research Design | 1 | 2016 | 5987 | 0.050 |
Why?
|
Brain Death | 1 | 2023 | 348 | 0.040 |
Why?
|
Algorithms | 1 | 2020 | 13881 | 0.040 |
Why?
|
Blood Coagulation | 1 | 2006 | 1127 | 0.040 |
Why?
|
Coronary Circulation | 1 | 2006 | 1572 | 0.040 |
Why?
|
Least-Squares Analysis | 1 | 2020 | 379 | 0.040 |
Why?
|
Guanylate Cyclase | 1 | 2020 | 201 | 0.040 |
Why?
|
Chest Pain | 1 | 2007 | 1114 | 0.040 |
Why?
|
Postoperative Complications | 2 | 2020 | 15295 | 0.040 |
Why?
|
Tissue Plasminogen Activator | 1 | 2006 | 1261 | 0.040 |
Why?
|
Gastrectomy | 1 | 2024 | 663 | 0.040 |
Why?
|
Inorganic Chemicals | 1 | 2018 | 10 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 2 | 2021 | 35421 | 0.040 |
Why?
|
Parasitemia | 1 | 2019 | 174 | 0.040 |
Why?
|
Death | 1 | 2023 | 678 | 0.040 |
Why?
|
Heparin | 1 | 2006 | 1637 | 0.040 |
Why?
|
C-Reactive Protein | 2 | 2021 | 3778 | 0.040 |
Why?
|
Dilatation, Pathologic | 1 | 2020 | 520 | 0.040 |
Why?
|
Electrocardiography | 2 | 2014 | 6442 | 0.040 |
Why?
|
Early Diagnosis | 2 | 2014 | 1184 | 0.040 |
Why?
|
Nucleotides | 2 | 2012 | 464 | 0.040 |
Why?
|
Lost to Follow-Up | 1 | 2019 | 105 | 0.040 |
Why?
|
Diagnosis, Differential | 2 | 2019 | 12959 | 0.040 |
Why?
|
Tachycardia, Ventricular | 1 | 2007 | 1273 | 0.040 |
Why?
|
Antibodies, Protozoan | 1 | 2019 | 253 | 0.040 |
Why?
|
Liver | 1 | 2014 | 7474 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2016 | 7181 | 0.040 |
Why?
|
Glucose | 1 | 2010 | 4397 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2016 | 14722 | 0.040 |
Why?
|
Ambulatory Care | 2 | 2023 | 2708 | 0.040 |
Why?
|
Neprilysin | 1 | 2020 | 439 | 0.040 |
Why?
|
Computational Biology | 1 | 2010 | 3521 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2020 | 10943 | 0.040 |
Why?
|
Adipokines | 1 | 2020 | 319 | 0.040 |
Why?
|
Israel | 1 | 2020 | 796 | 0.040 |
Why?
|
Denmark | 1 | 2019 | 738 | 0.040 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2019 | 712 | 0.040 |
Why?
|
Viremia | 1 | 2020 | 736 | 0.040 |
Why?
|
Motor Activity | 1 | 2007 | 2714 | 0.040 |
Why?
|
Placebos | 1 | 2021 | 1676 | 0.040 |
Why?
|
Cardiotonic Agents | 1 | 2020 | 535 | 0.040 |
Why?
|
Amino Acids | 2 | 2014 | 1736 | 0.040 |
Why?
|
Galectins | 1 | 2019 | 268 | 0.040 |
Why?
|
Heart Arrest | 1 | 2007 | 1470 | 0.040 |
Why?
|
Rats | 2 | 2015 | 24260 | 0.040 |
Why?
|
Motion | 1 | 2020 | 798 | 0.040 |
Why?
|
Bicycling | 1 | 2017 | 176 | 0.030 |
Why?
|
Keratan Sulfate | 1 | 2015 | 17 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2015 | 4933 | 0.030 |
Why?
|
Cell Line | 1 | 2010 | 15997 | 0.030 |
Why?
|
Brazil | 1 | 2019 | 1270 | 0.030 |
Why?
|
Mice, Inbred C57BL | 3 | 2021 | 21827 | 0.030 |
Why?
|
Odds Ratio | 1 | 2008 | 9849 | 0.030 |
Why?
|
Cross-Sectional Studies | 4 | 2020 | 25043 | 0.030 |
Why?
|
Mutation | 1 | 2019 | 29786 | 0.030 |
Why?
|
Disease Progression | 3 | 2019 | 13284 | 0.030 |
Why?
|
Atrial Fibrillation | 1 | 2013 | 5034 | 0.030 |
Why?
|
Ceramides | 1 | 2016 | 199 | 0.030 |
Why?
|
Weight Gain | 2 | 2016 | 2292 | 0.030 |
Why?
|
NF-kappa B | 1 | 2003 | 2499 | 0.030 |
Why?
|
Blood Proteins | 1 | 2019 | 1124 | 0.030 |
Why?
|
Exanthema | 1 | 2019 | 501 | 0.030 |
Why?
|
Ships | 1 | 2014 | 61 | 0.030 |
Why?
|
Heart Function Tests | 1 | 2015 | 330 | 0.030 |
Why?
|
Canada | 1 | 2019 | 2065 | 0.030 |
Why?
|
Administration, Topical | 1 | 2016 | 690 | 0.030 |
Why?
|
Tryptophan Hydroxylase | 1 | 2014 | 89 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 4751 | 0.030 |
Why?
|
Cell Culture Techniques | 1 | 2002 | 1678 | 0.030 |
Why?
|
Dyslipidemias | 2 | 2012 | 849 | 0.030 |
Why?
|
Drug Resistance | 1 | 2020 | 1609 | 0.030 |
Why?
|
Hypotension | 1 | 2020 | 884 | 0.030 |
Why?
|
Aspirin | 1 | 2006 | 3282 | 0.030 |
Why?
|
Atherosclerosis | 1 | 2010 | 3445 | 0.030 |
Why?
|
Hyperemia | 1 | 2015 | 225 | 0.030 |
Why?
|
Blood Pressure Determination | 1 | 2017 | 634 | 0.030 |
Why?
|
Gene Deletion | 1 | 2021 | 2751 | 0.030 |
Why?
|
Survival Analysis | 2 | 2018 | 10252 | 0.030 |
Why?
|
Advisory Committees | 1 | 2017 | 775 | 0.030 |
Why?
|
Models, Biological | 1 | 2010 | 9583 | 0.030 |
Why?
|
Adipocytes, White | 1 | 2014 | 89 | 0.030 |
Why?
|
Heterocyclic Compounds | 1 | 2014 | 249 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2018 | 2029 | 0.030 |
Why?
|
Adipocytes, Brown | 1 | 2014 | 144 | 0.030 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2019 | 851 | 0.030 |
Why?
|
Asymptomatic Diseases | 1 | 2016 | 551 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2008 | 19229 | 0.030 |
Why?
|
Receptor, erbB-2 | 1 | 2002 | 2416 | 0.030 |
Why?
|
PPAR alpha | 1 | 2014 | 197 | 0.030 |
Why?
|
Procollagen | 1 | 2012 | 185 | 0.030 |
Why?
|
Carbohydrates | 1 | 2014 | 394 | 0.030 |
Why?
|
Thyroid Hormones | 1 | 2014 | 390 | 0.030 |
Why?
|
Fever | 1 | 2019 | 1616 | 0.030 |
Why?
|
Cystatin C | 1 | 2012 | 250 | 0.020 |
Why?
|
Organ Size | 1 | 2016 | 2252 | 0.020 |
Why?
|
Bone Neoplasms | 1 | 2003 | 2529 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2016 | 1364 | 0.020 |
Why?
|
Genetic Markers | 1 | 2017 | 2634 | 0.020 |
Why?
|
Muscle Strength | 1 | 2015 | 592 | 0.020 |
Why?
|
Biogenic Amines | 1 | 2010 | 50 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 2020 | 2418 | 0.020 |
Why?
|
Renin | 1 | 2012 | 642 | 0.020 |
Why?
|
GABA Plasma Membrane Transport Proteins | 1 | 2010 | 30 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2023 | 5391 | 0.020 |
Why?
|
Physical Conditioning, Animal | 1 | 2014 | 362 | 0.020 |
Why?
|
Dicarboxylic Acids | 1 | 2010 | 69 | 0.020 |
Why?
|
Amino Acid Transport Systems | 1 | 2010 | 32 | 0.020 |
Why?
|
Mitral Valve Stenosis | 1 | 2012 | 376 | 0.020 |
Why?
|
Patient Selection | 1 | 2022 | 4215 | 0.020 |
Why?
|
Prostatic Neoplasms | 2 | 2003 | 11124 | 0.020 |
Why?
|
Glucose Metabolism Disorders | 1 | 2010 | 54 | 0.020 |
Why?
|
Sphingomyelins | 1 | 2010 | 105 | 0.020 |
Why?
|
Sampling Studies | 1 | 2011 | 623 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2020 | 6489 | 0.020 |
Why?
|
Fibrosis | 1 | 2016 | 2029 | 0.020 |
Why?
|
Reoperation | 1 | 2019 | 4201 | 0.020 |
Why?
|
Systems Integration | 1 | 2011 | 440 | 0.020 |
Why?
|
Glutamine | 1 | 2012 | 578 | 0.020 |
Why?
|
Intracellular Space | 1 | 2010 | 212 | 0.020 |
Why?
|
Organ Specificity | 1 | 2014 | 2008 | 0.020 |
Why?
|
Fontan Procedure | 1 | 2014 | 778 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2014 | 2187 | 0.020 |
Why?
|
Waist Circumference | 1 | 2012 | 917 | 0.020 |
Why?
|
Health Behavior | 1 | 2020 | 2636 | 0.020 |
Why?
|
Extracellular Space | 1 | 2010 | 594 | 0.020 |
Why?
|
Standard of Care | 1 | 2011 | 564 | 0.020 |
Why?
|
Dietary Proteins | 1 | 2012 | 963 | 0.020 |
Why?
|
Ketones | 1 | 2008 | 188 | 0.020 |
Why?
|
Biopsy | 1 | 2019 | 6756 | 0.020 |
Why?
|
Insulin-Secreting Cells | 1 | 2014 | 891 | 0.020 |
Why?
|
Uric Acid | 1 | 2012 | 766 | 0.020 |
Why?
|
Molecular Structure | 1 | 2011 | 1899 | 0.020 |
Why?
|
Outpatients | 1 | 2014 | 1486 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2018 | 3610 | 0.020 |
Why?
|
Carotid Artery Diseases | 1 | 2012 | 882 | 0.020 |
Why?
|
Phenols | 1 | 2010 | 497 | 0.020 |
Why?
|
Parents | 1 | 2020 | 3407 | 0.020 |
Why?
|
Death, Sudden, Cardiac | 1 | 2014 | 1541 | 0.020 |
Why?
|
Adenocarcinoma | 1 | 2003 | 6364 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2012 | 1782 | 0.020 |
Why?
|
Societies, Medical | 1 | 2017 | 3743 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2015 | 6622 | 0.020 |
Why?
|
Peptide Hydrolases | 1 | 2008 | 634 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2002 | 9274 | 0.020 |
Why?
|
Analgesics, Opioid | 1 | 2021 | 3674 | 0.020 |
Why?
|
Tumor Cells, Cultured | 2 | 2003 | 6314 | 0.020 |
Why?
|
Causality | 1 | 2011 | 1275 | 0.020 |
Why?
|
Glycolysis | 1 | 2008 | 827 | 0.020 |
Why?
|
Smoking Cessation | 1 | 2016 | 2071 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 2015 | 8301 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2016 | 9734 | 0.010 |
Why?
|
Databases, Factual | 1 | 2018 | 7729 | 0.010 |
Why?
|
Electrophoretic Mobility Shift Assay | 1 | 2003 | 300 | 0.010 |
Why?
|
Cluster Analysis | 1 | 2010 | 2715 | 0.010 |
Why?
|
Induced Pluripotent Stem Cells | 1 | 2014 | 1736 | 0.010 |
Why?
|
Fasting | 1 | 2008 | 1593 | 0.010 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3133 | 0.010 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3240 | 0.010 |
Why?
|
Blotting, Northern | 1 | 2003 | 1581 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2017 | 6234 | 0.010 |
Why?
|
Neuregulin-1 | 1 | 2002 | 142 | 0.010 |
Why?
|
Chick Embryo | 1 | 2003 | 982 | 0.010 |
Why?
|
Receptor, erbB-3 | 1 | 2002 | 142 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2012 | 6895 | 0.010 |
Why?
|
Boston | 1 | 2014 | 9313 | 0.010 |
Why?
|
Oxidative Stress | 1 | 2012 | 3086 | 0.010 |
Why?
|
Cholesterol, LDL | 1 | 2010 | 2356 | 0.010 |
Why?
|
Renal Dialysis | 1 | 2010 | 1786 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 7279 | 0.010 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2003 | 638 | 0.010 |
Why?
|
Coculture Techniques | 1 | 2003 | 1341 | 0.010 |
Why?
|
Risk | 1 | 2012 | 9687 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2014 | 7722 | 0.010 |
Why?
|
Child | 2 | 2019 | 77709 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 2002 | 2085 | 0.010 |
Why?
|
Pregnancy | 1 | 2020 | 29144 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2019 | 17446 | 0.010 |
Why?
|
Homeostasis | 1 | 2008 | 3340 | 0.010 |
Why?
|
Smoking | 1 | 2014 | 8987 | 0.010 |
Why?
|
Carrier Proteins | 1 | 2010 | 5021 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2014 | 11483 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 3870 | 0.010 |
Why?
|
Blotting, Western | 1 | 2003 | 5179 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2014 | 12072 | 0.010 |
Why?
|
Ligands | 1 | 2002 | 3282 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2002 | 20822 | 0.010 |
Why?
|
Androgens | 1 | 2002 | 1281 | 0.010 |
Why?
|
Cell Division | 1 | 2002 | 4568 | 0.010 |
Why?
|
Diet | 1 | 2012 | 7939 | 0.010 |
Why?
|
Transcription Factors | 1 | 2014 | 12208 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20129 | 0.010 |
Why?
|
Protein Binding | 1 | 2002 | 9386 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2002 | 13033 | 0.000 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2002 | 8428 | 0.000 |
Why?
|
Antineoplastic Agents | 1 | 2002 | 13695 | 0.000 |
Why?
|